Regeneron Pharmaceuticals (REGN) has seen remarkable performance, outperforming underlying earnings growth over the past five years. A collaboration is in progress with
Doudna-founded Mammoth on gene editing therapies. Intech Investment Management LLC has reduced its stake in REGN, while other firms such as
Empowered Funds LLC and Tokio Marine Asset Management Co. Ltd increased their investments. Furthermore, shares of REGN have also been purchased by
Envestnet Portfolio Solutions Inc. and Susquehanna Fundamental Investments LLC.Despite, reflectively lofty price targets by Piper Sandler and Guggenheim,
company insiders have sold around $26 million of REGN stocks, possibly signaling caution. The company's
Q1 2024 earnings missed the mark, amid lower sales of their key product, Eylea. Also,
Regeneron's lymphoma candidate was rejected by the FDA, adding further challenges. Despite these issues, investors see strength in the company's financial fundamentals and its stock price is near record highs. Notably, however, a shareholder lawsuit for accounting practice is under investigation by
Pomerantz Law Firm and Portnoy Law Firm. Overall, the circumstances mar a mixed picture for REGN's future investors.
Regeneron Pharmaceuticals REGN News Analytics from Wed, 06 Dec 2023 08:00:00 GMT to Sun, 21 Jul 2024 19:03:23 GMT -
Rating -2
- Innovation 3
- Information 8
- Rumor -3
